Patient P-03465
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Stable
Discontinuation risk
48%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S17
- Day 96 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 102 CR-01 recommended — Clinician Review CR-01
- Day 103 Patient accepted — Started CR-01 in the companion
- Day 108 Deterioration detected before clinical escalation — Clinician Review CR-01
What changed?
Trajectory began diverging from predicted response on Day 96.
Primary contributors, last 14 days
- Toxicity+8
- GI instability-5
- Nutritional resilience+4
- Inflammatory activity-2
What helped?
- Clinician Review CR-01Day 102Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
53%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 83% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 44/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Autonomic recovery ↓65
- WearableResting HR 73 bpm
- Wearable2,128 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 51
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 49
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Poor metabolizerHigher exposure at standard dose
Microbiome
Shannon diversity 2.4 · butyrate capacity 44/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 56 ms
- Sleep
- 6.1 h
- Steps
- 2,517
- Resting HR
- 72 bpm
Daily log: GI score 48, nutritional resilience 42, adherence 72.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03105 | 26% | S12 | AD-05 | no change | 60 |
| P-03204 | 25% | S16 | AD-05 | improved | 48 |
| P-03351 | 25% | S07 | AD-05 | no change | 51 |
| P-03482 | 25% | S05 | AD-05 | no change | 67 |
| P-03111 | 23% | S07 | AD-05 | no change | 48 |
| P-03187 | 23% | S12 | AD-05 | no change | 80 |
| P-03369 | 22% | S18 | AD-05 | no change | 37 |
| P-03424 | 22% | S12 | AD-05 | improved | 41 |
| P-03034 | 21% | S14 | AD-05 | no change | 30 |
| P-03208 | 22% | S02 | BR-03 | improved | 57 |
| P-03277 | 22% | S14 | BR-03 | improved | 41 |
| P-03166 | 42% | S20 | CR-01 | improved | 62 |